The introduction of new technology has revolutionized the way radiotherapy is delivered for bladder cancer: developing from the use of basic conventional techniques to a high precision, personalized approach. In order to demonstrate that the new technology is beneficial to the patient and to ensure its safe implementation, there is a need to integrate clinical expertise, patient values and research evidence into the development of evidencebased best practices (EBP). Since 2005, a series of prospective and retrospective studies were conducted to investigate different aspects of bladder radiotherapy, such as the accurate definition of treatment volumes, quantification of inter-and intrafractional bladder volumes changes and surface displacements, conformity and normal organ avoidance for dose distributions, mode and frequency of image-guidance interventions, reliability of image guidance surrogates and the cost/benefit of adaptive strategies. At each stage, the impact on geometric and dosimetric precision was quantified as evidence to substantiate the use of EBPs. Currently all bladder patients at our institution are treated with daily image guidance using CBCT with soft tissue alignment, with dose delivered to an individualized clinical target volume and planning target volume using IMRT. 
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Abstract text
Bladder preservation is increasingly being accepted as an important alternative to radical cystectomy for muscleinvasive urothelial cancers. This talk will cover the evidence for bladder preservation using radiotherapy with radiosensitisation, dose, fractionation and radiotherapy technique. There are no robust ways to stratify patients for treatment, but there are a number of promising candidates. An overview of novel biomarkers for stratification will be presented. 
To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected treatments. Here, we examined in a poorly immunogenic mouse breast cancer model the potential of antibody-based immunomodulation and conventional anti-cancer treatments to collaborate with anti-PD-1 treatment. One important requirement to improve anti-PD-1-mediated tumor control was to promote tumor-specific cytotoxic T cell (CTL) priming, which was achieved by stimulating the CD137 costimulatory receptor. A second requirement was to overrule PD-1-unrelated mechanisms of CTL suppression in the tumor micro-environment (TME). This was achieved by radiotherapy and cisplatin treatment. In the context of CD137/PD-1-targeting immunotherapy, radiotherapy allowed for tumor elimination by altering the TME, rather than intrinsic CTL functionality. Combining this radioimmunotherapy regimen with low-dose cisplatin improved CTL-dependent regression of a contralateral tumor outside the radiation field. Thus, systemic tumor control may be achieved by combining immunotherapy protocols that promote T cell priming with (chemo)radiation protocols that permit CTL activity in both the irradiated tumor and (occult) metastases.
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